Logo image of ENLV

ENLIVEX THERAPEUTICS LTD (ENLV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ENLV - IL0011319527 - Common Stock

0.959 USD
0 (-0.1%)
Last: 12/11/2025, 8:00:02 PM
0.9602 USD
+0 (+0.13%)
Pre-Market: 12/12/2025, 4:25:52 AM
Fundamental Rating

3

Taking everything into account, ENLV scores 3 out of 10 in our fundamental rating. ENLV was compared to 531 industry peers in the Biotechnology industry. While ENLV has a great health rating, there are worries on its profitability. ENLV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENLV had negative earnings in the past year.
In the past year ENLV has reported a negative cash flow from operations.
ENLV had negative earnings in each of the past 5 years.
ENLV had a negative operating cash flow in each of the past 5 years.
ENLV Yearly Net Income VS EBIT VS OCF VS FCFENLV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ENLV has a Return On Assets (-60.66%) which is comparable to the rest of the industry.
With a Return On Equity value of -72.66%, ENLV perfoms like the industry average, outperforming 54.80% of the companies in the same industry.
Industry RankSector Rank
ROA -60.66%
ROE -72.66%
ROIC N/A
ROA(3y)-59.69%
ROA(5y)-44.71%
ROE(3y)-71.64%
ROE(5y)-53.05%
ROIC(3y)N/A
ROIC(5y)N/A
ENLV Yearly ROA, ROE, ROICENLV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ENLV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENLV Yearly Profit, Operating, Gross MarginsENLV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

ENLV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ENLV has been increased compared to 5 years ago.
There is no outstanding debt for ENLV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENLV Yearly Shares OutstandingENLV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ENLV Yearly Total Debt VS Total AssetsENLV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ENLV has an Altman-Z score of 28.97. This indicates that ENLV is financially healthy and has little risk of bankruptcy at the moment.
ENLV has a Altman-Z score of 28.97. This is amongst the best in the industry. ENLV outperforms 92.84% of its industry peers.
ENLV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.97
ROIC/WACCN/A
WACCN/A
ENLV Yearly LT Debt VS Equity VS FCFENLV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 6.43 indicates that ENLV has no problem at all paying its short term obligations.
The Current ratio of ENLV (6.43) is better than 66.10% of its industry peers.
A Quick Ratio of 6.43 indicates that ENLV has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.43, ENLV is in the better half of the industry, outperforming 66.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.43
Quick Ratio 6.43
ENLV Yearly Current Assets VS Current LiabilitesENLV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.88% over the past year.
EPS 1Y (TTM)43.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 21.58% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.04%
EPS Next 2Y9.07%
EPS Next 3Y-2.91%
EPS Next 5Y21.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENLV Yearly Revenue VS EstimatesENLV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 200M 400M 600M 800M
ENLV Yearly EPS VS EstimatesENLV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENLV. In the last year negative earnings were reported.
Also next year ENLV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENLV Price Earnings VS Forward Price EarningsENLV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENLV Per share dataENLV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

ENLV's earnings are expected to decrease with -2.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.07%
EPS Next 3Y-2.91%

More info and screens

0

5. Dividend

5.1 Amount

ENLV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENLIVEX THERAPEUTICS LTD

NASDAQ:ENLV (12/11/2025, 8:00:02 PM)

Premarket: 0.9602 +0 (+0.13%)

0.959

0 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-30 2026-03-30
Inst Owners3.69%
Inst Owner Change-64.38%
Ins Owners4.53%
Ins Owner ChangeN/A
Market Cap226.60M
Revenue(TTM)N/A
Net Income(TTM)-12.70M
Analysts80
Price Target7.14 (644.53%)
Short Float %0.73%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.73%
Min EPS beat(2)26.47%
Max EPS beat(2)50.98%
EPS beat(4)3
Avg EPS beat(4)10.02%
Min EPS beat(4)-45.48%
Max EPS beat(4)50.98%
EPS beat(8)5
Avg EPS beat(8)2.19%
EPS beat(12)8
Avg EPS beat(12)3.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-30%
PT rev (3m)-30%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.38%
EPS NY rev (1m)-14.44%
EPS NY rev (3m)11.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.96
P/tB 12.96
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.66%
ROE -72.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.69%
ROA(5y)-44.71%
ROE(3y)-71.64%
ROE(5y)-53.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.43
Quick Ratio 6.43
Altman-Z 28.97
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)362.73%
Cap/Depr(5y)347.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y28.04%
EPS Next 2Y9.07%
EPS Next 3Y-2.91%
EPS Next 5Y21.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.5%
OCF growth 3YN/A
OCF growth 5YN/A

ENLIVEX THERAPEUTICS LTD / ENLV FAQ

What is the fundamental rating for ENLV stock?

ChartMill assigns a fundamental rating of 3 / 10 to ENLV.


What is the valuation status of ENLIVEX THERAPEUTICS LTD (ENLV) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENLIVEX THERAPEUTICS LTD (ENLV). This can be considered as Overvalued.


How profitable is ENLIVEX THERAPEUTICS LTD (ENLV) stock?

ENLIVEX THERAPEUTICS LTD (ENLV) has a profitability rating of 1 / 10.


How financially healthy is ENLIVEX THERAPEUTICS LTD?

The financial health rating of ENLIVEX THERAPEUTICS LTD (ENLV) is 8 / 10.